These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 23117948)

  • 21. Inclusion Body Myositis: Update on Pathogenesis and Treatment.
    Naddaf E; Barohn RJ; Dimachkie MM
    Neurotherapeutics; 2018 Oct; 15(4):995-1005. PubMed ID: 30136253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inclusion body myositis and sarcoid myopathy: coincidental occurrence or associated diseases.
    Sanmaneechai O; Swenson A; Gerke AK; Moore SA; Shy ME
    Neuromuscul Disord; 2015 Apr; 25(4):297-300. PubMed ID: 25599912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathogenesis of primary inflammatory myopathies].
    Benveniste O; Squier W; Boyer O; Hilton-Jones D; Herson S
    Presse Med; 2004 Nov; 33(20):1444-50. PubMed ID: 15611679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.
    Dourmishev LA
    Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclusion body myositis--a review.
    Vogel H
    Adv Anat Pathol; 1998 May; 5(3):164-9. PubMed ID: 9868522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on idiopathic inflammatory myopathies.
    Briani C; Doria A; Sarzi-Puttini P; Dalakas MC
    Autoimmunity; 2006 May; 39(3):161-70. PubMed ID: 16769649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunolocalization of FAS and FAS ligand in inflammatory myopathies.
    De Bleecker JL; Meire VI; Van Walleghem IE; Groessens IM; Schröder JM
    Acta Neuropathol; 2001 Jun; 101(6):572-8. PubMed ID: 11515785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclusion body myositis: a case of bilateral extremity weakness.
    Lam L; Scheper S; Zagorski N; Chung M; Noguchi H; Liow KK
    Hawaii J Med Public Health; 2013 Dec; 72(12):417-20. PubMed ID: 24377075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inclusion body myositis: clinical and pathological boundaries.
    Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ
    Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A rare case of inclusion body myositis associated with anti-PM/Scl-75 antibodies].
    Yamamoto M; Tsuzaki K; Itani K; Tachibana N; Inoue M; Hamano T
    Rinsho Shinkeigaku; 2020 Apr; 60(4):264-267. PubMed ID: 32238743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of inclusion body myositis.
    Cherin P
    Curr Opin Rheumatol; 1999 Nov; 11(6):456-61. PubMed ID: 10551668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myasthenia gravis with inclusion body myositis: A case report.
    Kakutani T; Yoshizawa M
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):83-85. PubMed ID: 37210209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inclusion body myositis: old and new concepts.
    Amato AA; Barohn RJ
    J Neurol Neurosurg Psychiatry; 2009 Nov; 80(11):1186-93. PubMed ID: 19864656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclusion body myositis: diagnosis, pathogenesis, and treatment options.
    Solorzano GE; Phillips LH
    Rheum Dis Clin North Am; 2011 May; 37(2):173-83, v. PubMed ID: 21444018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
    Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
    J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid-responsive inclusion body myositis associated with endometrial cancer.
    Alexandrescu DT; Bhagwati NS; Fomberstein B; Wolfe DE; Feliz A; Wiernik PH
    Clin Exp Rheumatol; 2005; 23(1):93-6. PubMed ID: 15789894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemokines in idiopathic inflammatory myopathies.
    De Paepe B; Creus KK; De Bleecker JL
    Front Biosci; 2008 Jan; 13():2548-77. PubMed ID: 17981734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymyositis: an overdiagnosed entity.
    van der Meulen MF; Bronner IM; Hoogendijk JE; Burger H; van Venrooij WJ; Voskuyl AE; Dinant HJ; Linssen WH; Wokke JH; de Visser M
    Neurology; 2003 Aug; 61(3):316-21. PubMed ID: 12913190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy.
    Das L; Blumbergs PC; Manavis J; Limaye VS
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):539-42. PubMed ID: 23343957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.
    Choi YC; Dalakas MC
    Neurology; 2000 Jan; 54(1):65-71. PubMed ID: 10636127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.